Related Experiment Video
Updated: Jul 11, 2026

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
Published on: April 10, 2026
Clinical results with pizotyline in depression
1Department of Psychiatry, Columbus Hospital, New York, New York, USA.
Abstract:
Pizotyline at two dosage levels or one dosage level of amitriptyline were administered under double-blind conditions to 100 depressed out-patients in a community mental health clinic; 73 patients completed the four-week study. Their psychological response was assessed with four ECDEU rating scales and a psychiatrist's clinical examination. Their physiological response was measured with standard hematology tests, blood chemistries, and urinalyses. Statistical analyses of the results showed one significant difference among the three treatment groups' responses: sleep disturbance decreased significantly (p < 0.05) more in patients receiving the higher pizotyline dosage. The three treatment groups' responses measured by the other rating scale items did not differ significantly. Ten of the 75 patients taking pizotyline and four of the 25 patients taking amitriptyline developed side effects. To clarify dose-and time-related variables, additional studies would be required.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Psychosis: Goals of Pharmacotherapy
Depressive Disorders: MDD and Dysthymia
Depression: Overview
Long-term Depression
Calcium Ion Concentration Mechanism
If over time, all...
Long-term Depression
